Antiretroviral therapy (ART) for HIV is vulnerable to unplanned treatment interruptions–consecutively missed doses over a series of days–which can result in virologic rebound. Yet clinicians lack a si
Race/ethnicity-specific proportion of beneficiaries with non-persistence and low adherence who initiated antihypertensive medication and low adherence among those who were persistent by two-year calen
Association between experiencing side effects of artesunate/amodiaquine malaria chemoprevention (ASAQ-CP) in the first round of mass drug administration (MDA) with initiation of ASAQ-CP in the second
